Hiddo L. Heerspink - Publications

Efficacy and safety of canagliflozin are consistent across polypharmacy burden in CKD: the CREDENCE trial.

Journal: Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association

Published: September 04, 2026

Leave no one behind: optimizing kidney protection in type 1 diabetes.

Journal: Nature reviews. Nephrology

Published: August 13, 2026

Design and baseline characteristics of the ZENITH high proteinuria trial testing zibotentan/dapagliflozin efficacy in CKD.

Journal: Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association

Published: August 04, 2026

Finerenone in hypertensive non-diabetic chronic kidney disease: a FIND-CKD subgroup analysis.

Journal: European heart journal

Published: July 24, 2026

SGLT2 inhibition modulates metabolic, vascular, and inflammatory molecular markers in the kidney in youth with type 1 diabetes.

Journal: Science translational medicine

Published: July 22, 2026

More Evidence, More Options, More Questions.

Journal: Journal of the American Society of Nephrology : JASN

Published: July 08, 2026

Sex disparities in receiving evidence-based medications in patients with CKD.

Journal: Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association

Published: June 19, 2026